Welcome to Grünenthal. This site uses cookies. Read our policy.

Accept Cookies

PainSolve: we aspire to solve pain


Gabriel Baertschi Chief Executive Officer (CEO) Grünenthal Group

Gabriel Baertschi, Chairman of the Corporate Executive Board, Chief Executive Officer

“Welcome to PainSolve, our platform for connecting pain experts around the globe to discuss open research questions and recent findings to improve the lives of patients in need. Pain is not a symptom: It’s a disease in its own right and needs to be addressed with innovative treatments. At Grünenthal, we can look back on decades of experience in pain management. We now want to join forces with you to make a genuine difference in the life of patients affected by pain.”

Gabriel Baertschi

Chairman of the Corporate Executive Board, Chief Executive Officer

Why we care.

Chronic pain is a burden suffered by millions worldwide.
Its effects are complex and far-reaching, leaving patients and their families often without effective therapy – feeling helpless.

PainSolve is a research community for all those interested in tackling the burden of chronic pain.
It is a resource and platform for pain research; together, we want to better understand pain and work towards better pain solutions.

We are openly sharing our extensive knowledge in several areas of pain.
This includes our interactive body map of almost 100 pain conditions.

Register now to access a downloadable pain module library and case studies in niche pain conditions

Targeting TRPV

Transient receptor potential (TRP) ion channels are involved in nociception and play roles in several types of pain, including inflammatory pain, neuropathic pain and visceral pain. Pharmacological modulation of TRP channels may provide an alternative to opioid- or NSAID-based pain treatments. Here we review developments in this promising approach to pain management.

... Discover more

Placebo Effect and Pain - Part 2

In the second instalment of this 2-part article, we consider how researchers designing clinical trials for pain management can adapt their trial methodologies to take account of the placebo response. Various options to reduce the likelihood of ‘false negative’ trial outcomes when investigating novel options for chronic pain are proposed.

... Discover more